Loading market dashboard

Estimates, scoring, valuation assumptions, and peer comparison in one research surface.
Protalix BioTherapeutics, Inc. · Forecast overview
Bars show expected revenue while the line tracks expected EPS.
| Period | Revenue avg | Revenue range | EBITDA | EPS avg | Analysts |
|---|---|---|---|---|---|
| Dec 2028 | $67.46M | $63.38M - $71.55M | -$6.44M | $0.01 | 1 |
| Dec 2027 | $67.56M | $59.02M - $76.10M | -$6.45M | $0.05 | 2 |
| Dec 2026 | $78.30M | $78.00M - $78.58M | -$7.47M | $0.195 | 2 |
| Dec 2025 | $62.00M | $57.73M - $66.27M | -$5.92M | $0.03 | 2 |
| Dec 2024 | $53.94M | $53.38M - $54.49M | -$5.15M | $0.015 | 2 |
| Dec 2023 | $38.05M | $35.75M - $40.36M | -$3.63M | -$0.202 | 1 |
| Dec 2022 | $45.14M | $40.90M - $49.38M | -$21.55M | -$0.39 | 1 |
| Dec 2021 | $37.59M | $34.06M - $41.12M | -$19.24M | -$0.59 | 1 |
| Dec 2020 | $55.31M | $50.12M - $60.51M | -$3.65M | -$0.335 | 1 |
| Dec 2019 | $47.20M | $42.77M - $51.63M | -$3.11M | -$1.88 | 1 |
| Dec 2018 | $18.60M | $16.85M - $20.35M | -$1.23M | -$2.90 | 1 |
| Dec 2017 | $27.76M | $25.15M - $30.37M | -$1.83M | -$4.50 | 5 |